Genetically engineered insulin analogs: Diabetes in the new millenium

Pharmacological Reviews

Volumn 52, Issue 1, 2000, Pages 1-9

  Vajo, Zoltan ^a   Duckworth, William C ^a  

^a CARL T HAYDEN VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPART; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; NOVOSOL BASAL; UNCLASSIFIED DRUG; WW 99S32;

BLOOD GLUCOSE MONITORING; DIABETES MELLITUS; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG STABILITY; GENETIC ENGINEERING; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW;

AMINO ACID SEQUENCE; ANIMALS; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MOLECULAR SEQUENCE DATA; RECOMBINANT PROTEINS;

EID: 0034048940     PISSN: 00316997     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Antsiferov M, Woodworth JR, Mayorov A, Ristic S and Dedov I (1995) Within patient variability in postprandial glucose excursion with Lispro insulin analog compared with regular insulin (Abstract). Diabetologia 38(Suppl 1):A190.
2. Anderson JH Jr, Brunelle RL, Koivisto VA, Pfutzner A, Trautmann ME, Vignati L and DiMarchi R (1997) Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment: Multicenter Insulin Lispro Study Group. Diabetes 46:265-270.
3. Anderson J, Symanowski S and Brunelle R (1994) Safety of [Lys(B28), Pro(B29) human insulin] analog in long-term clinical trials (Abstract). Diabetes 43 (Suppl 1):61A.
4. Attia N, Jones TW, Holcombe J and Tamborlane WV (1998) Comparison of human regular and Lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM. Diabetes Care 21:817-821.
5. Bahr M, Kolter T, Seipke G and Eckel J (1997) Growth promoting and metabolic activity of the human insulin analog [GlyA21, ArgB31, ArgB32]insulin (HOE 901) in muscle cells. Eur J Pharmacol 320:259-265.
6. Berger M (1989) Towards more physiological insulin therapy in the 1990s. Diab Res Clin Pract 6:S25-S31.
7. Berti L, Kellerer M, Bossenmaier B, Seffer E, Seipke G and Haring HU (1998) The long acting human insulin analog HOE 901: Characteristics of insulin signalling in comparison to Asp(B10) and regular insulin. Horm Metab Res 30:123-129.
8. Binder C, Lauritzen T, Faber O and Pramming S (1984) Insulin pharmacokinetics. Diabetes Care 7:188-199.
9. Bornfeldt KE, Gidlof RA, Wasteson A, Lake M, Skottner A and Arnqvist HJ (1991) Binding and biological effect of insulin, insulin analogs and insulin-like growth factors in rat aortic smooth muscle cells: Comparison of maximal growth promoting activities. Diabetologia 34:307-313.
10. Brange J (1997) The new era of biotech insulin analogs. Diabetologia 40:S48-S53.
11. Brange J, Ribel U, Hansen JF, Dodson G, Hansen MT, Havelund S, Melberg SG, Norris F, Morris K and Snel L (1988) Monomeric insulins obtained by protein engineering and their medical implications. Nature 333:679-682.
12. Brems DN, Brown PL, Bryant C, Chance RE, Green LK, Long HB, Miller AA, Millican R, Shields JE and Frank BH (1992) Improved insulin stability through amino acid substitution. Protein Eng 5:519-25.
13. Brunelle BL, Llewelyn J, Anderson JH Jr, Gale EA and Koivisto VA (1998) Metaanalysis of the effect of insulin Lispro on severe hypoglycemia in patients with type 1 diabetes. Diabetes Care 21:1726-31.
14. 1C in type 1 diabetes on physiologic intensive therapy with Lispro insulin at mealtime. Diabetes Care 22:795-800.
15. Dall V (1999) Preclinical safety pharmacology studies on the rapid-acting insulin analog insulin aspart. Arzneimittelforschung 49:463-470.
16. Del Sindaco P, Ciofetta M, Lalli C, Perriello G, Pampanelli S, Torlone E, Brunetti P and Bolli GB (1998) Use of the short-acting insulin analog Lispro in intensive treatment of type 1 diabetes mellitus: importance of appropriate replacement of basal insulin and time-interval injection-meal. Diabet Med 15:592-600.
17. Desmet M, Rutters A, Schmitt H and Satter E (1994) [Lys (B28), Pro (B29)] human insulin (LysPro): patients treated with LysPro vs human regular insulin - quality of life assesment (Abstract). Diabetes 43(Suppl 1):167A.
18. Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and the progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977-978.
19. Drejer K (1992) The bioactivity of insulin analogs from in vitro receptor binding to in vivo glucose uptake. Diabetes Metab Rev 8:259-86.
20. Drejer K, Kruse V, Larsen UD, Hougaard P, Bjorn S and Gammeltoft S (1991) Receptor binding and tyrosine kinase activation by insulin analogs with extreme affinities studied in human hepatoma HepG2 cells. Diabetes 40:1488-1495.
21. Dreyer M, Pein M, Schmidt B, Heidtmann B, Schlunzen M and Rosskamp R (1994) Comparison of the pharmacokinetics/dynamics of GLY(A21)-ARG(B31, B32)-human-insulin (HOE71GT) with NPH-insulin following subcutaneous injection by using euglycemic clamp technique (Abstract). Diabetologia 37 (Suppl 1):A78.
22. Duckworth WC (1997) Tumor necrosis factor and insulin resistance: Specificity of sequence accounts of inhibition of insulin action. J Lab Clin Med 130:114-115.
23. Fineberg NS, Fineberg SE, Anderson JH, Birkett MA, Gibson RG and Hufferd S (1996) Immunologic effects of insulin Lispro [Lys(B28), Pro(B29) human insulin] in IDDM and NIDDM patients previously treated with insulin. Diabetes 45:1750-1754.
24. Galloway JA, Hooper SA, Spradlin CT, Howey DC, Frank BH, Bowsher RR and Anderson JH (1992) Biosynthetic human proinsulin. Review of chemistry, in vitro and in vivo receptor binding, animal and human pharmacology studies, and clinical trial experience. Diabetes Care 15:666-692.
25. Garg SK, Anderson JH, Perry SV, Mackenzie T, Keith P, Jennings MK, Hansen MM and Chase HP (1999) Long-term efficacy of humalog in subjects with Type 1 diabetes mellitus. Diabet Med 16:384-387.
26. Gershonov E, Shechter Y and Fridkin M (1999) Spontaneous conversion of an inactive modified insulin to the active hormone in circulation: 9-Fluorenylmethoxycarbonil derivative of insulin. Diabetes 48:1437-1442.
27. Hamel FG, Siford GL, Fawcett J, Chance RE, Frank BH and Duckworth WC (1999) Differences in the cellular processing of AspB10 human insulin compared with human insulin and LysB28ProB29 human insulin. Metabolism 48:611-617.
28. Hansen BF, Danielsen GM, Drejer K, Sorensen AR, Wiberg FC, Klein HH and Lundemose AG (1996) Sustained signalling from the insulin receptor after stimulation with insulin analogs exhibiting increased mitogenic potency. Biochem J 315:271-279.
29. Heinemann L (1995) Do insulin-treated diabetic patients use an injection-meal-interval in daily life? Diabet Med 12:449-450.
30. Heinemann L, Sinha K, Weyer C, Loftager M, Hirschberger S and Heise T (1999) Time-action profile of the soluble, fatty acid acylated, long-acting insulin analog NN304. Diabet Med 16:332-338.
31. Heinemann L, Starke AAR, Hohmann A and Berger M (1992) Timing between the subcutaneous administration of insulin and consumption of a carbohydrate rich meal. Horm Metab Res 26 (Suppl):137-139.
32. Heinemann L, Weyer C, Rauhaus M, Heinrichs S and Heise T (1998) Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart. Diabetes Care 21:1910-1914.
33. Henrichs HR, Unger H, Trautmann ME and Pfutzner A (1996) Severe insulin resistance treated with insulin Lispro (letter). Lancet 348:1248.
34. Home PD, Lindhohn A, Hylleberg B and Round P (1998) Improved glycemic control with insulin aspart: A multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group. Diabetes Care 21:1904-1909.
35. Howey DC, Bowsher RR, Brunelle RL and Woodworth JR (1994) [Lys(B28), Pro(B29)]-human insulin: A rapidly absorbed analog of human insulin. Diabetes 43:396-402.
36. Howey DC, Woodworth JR, Bowsher RR and Reviergo J (1997) Pharmakcokinetic and glucodynamic assessments of palmitoyl, LYS (B29) human insulin in healthy volunteers (Abstract). Diabetologia 40 (Suppl 1):A354.
37. Janssen MM, Casteleijn S, Deville W, Popp-Snijders C, Roach P and Heine RJ (1997) Nighttime insulin kinetics and glycemic control in type 1 diabetes patients following administration of an intermediate-acting Lispro preparation. Diabetes Care 20:1870-873.
38. Jehle PM, Aisenpreis U, Bundschu D and Keller F (1999) Advantages of insulin Lispro (short-acting) in terminal kidney failure. Fortschr Med 117:41-42.
39. Jorgensen LN, Dideriksen LH and Drejer K (1992) Carcinogenic effect of the human insulin analog B-10 Asp in female rats (Abstract). Diabetologia 35 (Suppl 1):A3.
40. Jorgensen LN and Nielsen FS (1990) Timing of premeal insulins in diabetic patients on a multiple daily injection regimen: a questionnaire study (Abstract). Diabetologia 33 (Suppl 1):A116.
41. Jorgensen S and Drejer K (1990) Insulin analogs and nasal insulin delivery, in New Antidiabetic Drugs, 1st ed. (Bailey CJ and Flatt PR eds) pp 83-92, Smith-Gordon, London.
42. Jorgensen S, Vaag A, Langkjaer L, Hougaard P and Markussen J (1989) NovoSol Basal: pharmakokinetics of a novel soluble long acting insulin analog. BMJ 299: 415-459.
43. Kang S, Creagh FM, Ara J, Owens DR and Peters JR (1991) Insulin analogs and human insulin: Near-equivalent in vivo biological activity in healthy males in spite of widely different in vitro potencies (Abstract). Diabetes 40 (Suppl 1):243A.
44. Karounos DG, Bryson JS and Cohen DA (1997) Metabolically inactive insulin analog prevents type I diabetes in prediabetic NOD mice. J Clin Invest 100: 1344-1348.
45. Karsidag K, Satman I, Dinccag N, Altunas Y, Karadeniz S and Yilmaz MT (1996) Comparison of metabolic control in IDDM with two different intensive regimens of [Lys(B28), Pro(B29)] human insulin (Lispro) plus NPH insulin (Abstract). Diabetologia 39 (Suppl 1):A222.
46. Kotsanos JG, Vignati L, Huster W, Andrejasich C, Boggs MB, Jacobson AM, Marrero D, Mathias SD, Patrick D, Zalani S and Anderson J (1997) Health-related quality-of-life results from multinational clinical trials of insulin Lispro. Assessing benefits of a new diabetes therapy. Diabetes Care 20:948-958.
47. Kurtzhals P, Havelund S, Jonassen I, Kiehr B, Larsen UD, Ribel U and Markussen J (1995) Albumin binding of insulins acylated with fatty acids: Characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem J 312:725-731.
48. Kurtzhals P, Havelund S, Jonassen I and Markussen J (1997) Effect of fatty acids and selected drugs on the albumin binding of a long-acting, acylated insulin analog. J Pharm Sci 86:1365-1368.
49. Lahtela JT, Knip M, Paul R, Antonen J and Salmi J (1997) Severe antibody-mediated human insulin resistance: Successful treatment with the insulin analog Lispro. A case report. Diabetes Care 20:71-73.
50. Lalli C, Ciofetta M, Del Sindaco P, Torlone E, Pampanelli S, Compagnucci P, Cartechini MG, Bartocci L, Brunetti P and Bolli GB (1999) Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog Lispro in variable combination with NPH insulin at mealtime. Diabetes Care 22:468-477.
51. 125I-insulin absorption and blood glucose concentration. Diabetologia 17:291-295.
52. Lavelle-Jones M, Scott MH, Kolterman O, Rubenstein AH, Olefsky JM and Moossa AR (1987) Selective suppression of hepatic glucose output by human proinsulin in the dog. Am J Physiol 252:E230-E236.
53. Lindholm A, McEwen J and Riis AP (1999) Improved postprandial glycemic control with insulin aspart. A randomized double-blind cross-over trial in type 1 diabetes. Diabetes Care 22:801-805.
54. Lougheed WD, Zinman B, Strack TR, Janis LJ, Weymouth AB, Bernstein EA, Korbas AM and Frank BH (1997) Stability of insulin Lispro in insulin infusion systems. Diabetes Care 20:1061-1065.
55. Markussen J, Havelund S, Kurtzhals P, Andersen AS, Halstrom J, Hasselager E, Larsen UD, Ribel U, Schaffer L, Vad K and Jonassen I (1996) Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia 39:281-288.
56. Matthews DR and Pfeiffer C (1998) A new long-acting insulin (HOE 901) demonstrates less nocturnal hypoglycemia when compared with protamine insulin in a clinical trial (Abstract). Diabetologia 41 (Suppl 1):A245.
57. Mosekilde E, Jensen KS, Binder C, Pramming S and Thorsteinson B (1989) Modelling absorption kinetics of subcutaneous injected soluble insulin. J Pharmacokinet Biopharm 17:67-87.
58. Myers SH, Yakubu-Madus FE, Johnson WT, Baker JE, Cusick TS, Williams VK, Tinsley FC, Kriauciunas A, Manetta J and Chen VJ (1997) Acylation of human insulin with palmitic acid extends the time action of human insulin in diabetic dogs. Diabetes 46:637-642.
59. Nielsen FS, Jorgensen LN, Ipsen M, Voldsgaard AI and Parving HH (1995) Long-term comparison of human insulin analog B10Asp and soluble human insulin in IDDM patients on a basal/bolus insulin regimen. Diabetologia 38:592-598.
60. Pen P, Hinselmann C, Pfutzner A and Dreyer M (1996) Catheter disconnection in type 1 diabetes treated with CSII: Comparison of insulin Lispro and human regular insulin (Abstract). Diabetologia 39 (Suppl 1):A847.
61. Pfutzner A, Kustner E, Forst T, Schulze-Schleppinghoff B, Trautmann ME, Haslbeck M, Schatz H and Beyer J (1996) Intensive insulin therapy with insulin Lispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodes. Exp Clin Endocrinol Diabetes 104:25-30.
62. Pieber T, Eugene-Jolchine I and DeRobert E (1998) Efficacy and safety of HOE 901 in patients with type 1 diabetes: A four-week randomized, NPH insulin-controlled trial (Abstract). Diabetes 47 (Suppl 1):A62.
63. Radziuk J, Pye S, Bradley B, Braaten J, Vignati L, Roach P, Bowsher R, DiMarchi R and Chance R (1998) Basal activity profiles of NPH and [Nepsilon-palmitoyl Lys (B29)] human insulins in subjects with IDDM. Diabetologia 41:116-120.
64. Raskin P, Park G and Zimmerman J (1998) The effect of HOE 901 on glycemic control in type 2 diabetes (Abstract). Diabetes 47 (Suppl 1):A103.
65. Rassam AG, Zeise TM, Burge MR and Schade DS (1999) Optimal administration of Lispro insulin in hyperglycemic type 1 diabetes. Diabetes Care 22:133-136.
66. Renner R, Pfutzner A, Trautmann M, Harzer O, Sauter K and Landgraf R (1999) Use of insulin Lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group. Diabetes Care 22:784-788.
67. Revers RR, Henry R, Schmeiser L, Kolterman O, Cohen R, Bergenstal R, Polonsky K, Jaspan J, Rubenstein A and Frank B (1984) The effects of biosynthetic human proinsulin on carbohydrate metabolism. Diabetes 33:762-770.
68. Roach P, Trautmann M, Arora V, Sun B and Anderson JH Jr (1999) Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin Lispro-protamine formulations, insulin Lispro mix25 and insulin Lispro mix50. Mix50 Study Group. Clin Ther 21:523-534.
69. Roach P, Varshavsky JA, Gantner K and Anderson JH (1996) Insulin antibody formation during treatment with human insulin or insulin Lispro does not affect insulin dose requirements (Abstract). Diabetes 45 (Suppl 2):261A.
70. Rosenstock J, Park G and Zimmermann J (1998) Efficacy and safety of HOE 901 in patients with type 1 DM: A four-week randomized, NPH insulin-controlled trial (Abstract). Diabetes 47 (Suppl 1):A92.
71. Rosenstock J, Schwartz S, Clark C, Edwards M and Donley D (1999) Efficacy and safety of HOE 901 (Insulin Glargine) in subjects with type 2 DM: A 28-week randomized, NPH insulin-controlled trial (Abstract). Diabetes 48 (Suppl 1):A100.
72. Rosskamp RH and Park G (1999) Long-acting insulin analogs. Diabetes Care 22 (Suppl 2):B109-B113.
73. Schwartz GP, Thompson Burke G and Katsoyannis PG (1987) A superactive insulin: [B10-Aspartic acid]insulin(human). Proc Natl Acad Sci USA 84:6408-6411.
74. Shojaee-Moradie F, Eckey H, Jackson NC, Schuttler A, Brandenburg D, Sonksen PH and Jones RH (1998) Novel hepatoselective insulin analogs: Studies with covalently linked thyroxyl-insulin complexes. Diabet Med 15:928-936.
75. Shojaee-Moradie F, Jackson NC, Boroujerdi M, Brandenburg D, Sonksen PH and Jones RH (1995) Demonstration of a relatively hepatoselective effect of covalent insulin dimers on glucose metabolism in dogs. Diabetologia 38:1007-1013.
76. Slieker LJ, Brooke GS and Chance RE (1994) Insulin and IGF-I analogs: Novel approaches to improved insulin pharmacokinetics. Current directions in insulin-like growth factor research, in Advances in Experimental Medicine and Biology (LeRoith D and Raizada MK eds) vol 343, pp 25-32, Plenum Press, New York.
77. Slieker LJ and Sundell K (1991) Modifications in the 28-29 position of the insulin B-chain alter binding to the IGF-I receptor with minimal effect on insulin receptor binding (Abstract). Diabetes 40 (Suppl 1):168A.
78. Spradlin CT, Galloway JA and Anderson JH (1990) Apparent increase in coronary heart disease with human proinsulin (HPI) - randomization failure or HPI effect (Abstract) Diabetologia 33 (Suppl):A60.
79. Talaulicar M, Willms B and Rosskamp R (1996) HOE 901, ein neues Insulinanalog zur Substitution des basalen Insulin-bedarfs bei Type I Diabetes. Diabetes und Stoffwechsel 5:3-6.
80. Torlone E, Fanelli C, Rambotti AM, Kassi G, Modarelli F, Di Vincenzo A, Epifano L, Ciofetta M, Pampanelli S and Brunetti P (1994) Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analog [Lys(B28), Pro(B29)] in IDDM. Diabetologia 37:713-720.
81. Weyer C, Heise T and Heinemann L (1997) Insulin aspart in a 30/70 premixed formulation. Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture. Diabetes Care 20:1612-1614.
82. Ziel FH, Davidson MB, Harris MD and Rosenberg CS (1988) The variability in the action of unmodified insulin is more dependent on changes in tissue insulin sensitivity than on insulin absorption. Diabet Med 5:662-666.
83. Zinman B, Tildesley H, Chiasson JL, Tsui E and Strack TR (1997) Insulin Lispro in CSII: Results of a double-blind cross-over study. Diabetes 46:440-443.